Skip to content

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Transthyretin Amyloidosis | ATTR-CM | hATTR | ATTR-Mixed | ATTR | ATTRv-PN

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Patient willing and able to provide written informed consent to participate in the study
* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
* Aged ≥18 years at the time of signing the informed consent
* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)

Exclusion Criteria:

* Concurrent participation in any interventional trial for ATTR amyloidosis
* Involvement in the planning and/or conduct of the current study
* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Lieu de l'étude

Research Site
Research Site
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Research Site
Research Site
London, Ontario
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
AstraZeneca
Participants recherchés
Plus d'informations
ID de l'étude: NCT06465810